Table 2.
Drug loss on the simulated way to the lesion and distribution of drug/additive following PTA in peripheral and coronary arteries of pigs
| n | Paclitaxel-resveratrol-coated balloons 5.0 or 7.0 × 40 mm, 0.035’’ guide wire lumen | Paclitaxel-resveratrol-coated balloons 3.5–20 mm, 0.014’’ guide wire lumen | |
|---|---|---|---|
| Loss during passage through valve, sheath, and blood (in vitro) (% of dose) | 3/4 | 5.1 ± 2.6 | 0.6 ± 6.3 |
| Treatment site | External iliac artery | Coronary arteries | |
| Paclitaxel at or on balloon in artery (% of dose) | 4 | 65 ± 13 | Not done |
| Resveratrol at or on balloon in artery (% of dose) | 4 | 60 ± 15 | Not done |
| Paclitaxel in arterial wall (µg) (µg/g ~ ng/mg tissue) |
8 | 266 ± 229 145 ± 50 |
65 ± 28 126 ± 64 |
| Paclitaxel in arterial wall (% of dose) | 8 | 7.1 ± 6.1 | 7.8 ± 3.4 |
| Resveratrol in arterial wall (µg) | 8 | 22 ± 25 | < LOQ |
| Residual paclitaxel on balloons (% of dose) | 8 | 9.6 ± 8.7 | 25.4 ± 16.0 |
| Residual resveratrol on balloons (% of dose) | 8 | 13.8 ± 4.7 | 23.3 ± 12.1 |
n number of balloon catheters or arteries